For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?T ...

Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 56 cents for the first quarter of 2024, up 19.1% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 9.8% and also exceeded the company’s adjusted earnings per share guidance range of 50-52 cents per share.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the first ...

Key TakeawaysBoston Scientific exceeded first-quarter profit and sales forecasts on demand for its cardiovascular devices.The results were lifted by regulatory approval and launch of its product to treat irregular heartbeats.The news sent shares of Boston Scientific to an all-time high. Shares of Boston Scientific (BSX) hit an all-time high Wednesday as the maker of medical equipment reported better-than-anticipated quarterly results and boosted its guidance on demand for its cardiovascular devices, includi ...

Boston Scientific Corporation (NYSE:BSX) Q1 2024 Earnings Conference Call April 24, 2024 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Rick Wise - Stifel Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Travis Steed - Bank of America ...

For the quarter ended March 2024, Boston Scientific (BSX) reported revenue of $3.86 billion, up 13.8% over the same period last year. EPS came in at $0.56, compared to $0.47 in the year-ago quarter.The reported revenue represents a surprise of +4.85% over the Zacks Consensus Estimate of $3.68 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +9.80%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

Boston Scientific (BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.80%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of 7.84%.Over the last four qua ...

Q1 2024 Highlights April 24, 2024 1 Q1 2024 Financial & Operational Highlights | April 24, 2024 Safe Harbor for Forward-Looking Statements and Use of Document Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "i ...

Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared ...

MARLBOROUGH, Mass., April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per share (EPS), compared to $300 million or $0.21 per share a year ago, ...

Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2024 results on Apr 24, before the opening bell.In the last reported quarter, the company’s earnings per share of 55 cents exceeded the Zacks Consensus Estimate by 7.8%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.37%, on average.Factors at PlayWith U.S. hospitals expected to report an increase in procedure volumes through the months of 202 ...